AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilokibart, showing promising Phase 2 results for skin clearance, and a combination therapy for asthma. The deal, approved by both companies' boards, is expected to close in Q3 2026 pending regulatory and shareholder approval. AbbVie expects the acquisition to strengthen its immunology portfolio and be accretive to earnings by 2032.
AbbVie announced it will acquire Apogee Therapeutics, a clinical-stage biotech company, for approximately $10.9 billion. This acquisition gives AbbVie control over Apogee's diverse pipeline of clinical-stage candidates focused on inflammatory and imm...
The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disord...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, pote...
The Schwab U.S. Dividend Equity ETF (SCHD) provides investors with a low-cost, diversified portfolio of U.S. companies known for consistent dividend growth, making it an attractive option for those seeking a stable and growing income stream in retire...
